This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Express Scripts in Fast Lane

Express Scripts (ESRX - Get Report) just keeps on getting healthier.

The giant pharmacy benefit manager has been flexing its muscles all year and, just this week, promised even more powerful results to come. The company said late Monday it now expects to deliver a 2006 profit of between $3.10 and $3.22 a share -- even after 10 cents' worth of options expense -- instead of the $2.98 Wall Street had been anticipating. The company pointed to a variety of forces, ranging from rising generic drug use to specialty pharmacy growth, as major profit drivers.

"We have a great opportunity in 2006 to continue to provide value-added, fully integrated pharmacy benefit management services that will help our clients continue to better manage their drug trend," Express Scripts CEO George Paz said when he offered the company's much-awaited update. "Our positive outlook for 2006 reflects the strength of our core business and the success of our business model."

The company's stock jumped 3.2% to $83.34 following that forecast.

Early Calls

By now, investors have come to expect plenty from PBMs in general and Express Scripts in particular. Express Scripts' stock has proven to be a star performer already, rocketing past the broader market -- and even rivals Medco (MHS) and Caremark (CMX) -- over the past year. Thus, many people have assumed that the company would send more good news their way.

In a brief note published on Monday morning, SG Cowen analyst Kemp Dolliver portrayed the company's 2006 outlook as little more than a "short-term risk" to the stock. If anything, Dolliver assumed that the stock would at least hold steady.

Double Your Pleasure
Express Scripts accelerates

But J.P. Morgan analyst Lisa Gill felt more uneasy. After watching the stock more than double in a year, Gill began urging investors this month to start cashing in their profits ahead of the company's update. She questioned whether Express Scripts would continue to enjoy its current level of success next year.

"While growth in profitability metrics has been impressive in 2005, we do not believe this level of improvement will be sustainable going forward, as we believe ESRX has been playing catch-up and much of the low-hanging fruit has been realized," wrote Gill, who has a neutral rating on the company's stock. But "our primary area of concern relates to new business trends heading into 2006."

Specifically, Gill worries that Express Scripts will see $1 billion worth of business disappear in 2006. She cites the PBM's big contract with New York -- lost after Attorney General Eliot Spitzer launched a probe of the company -- as just one piece of business that could prove difficult to replace.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs